Royalty Pharma (RPRX) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Royalty Pharma (RPRX) over the past year, gaining 95.2% versus a gain of 57.2%. Over five years, TEVA leads with a +304.8% price change compared with +47.9% for RPRX. Teva Pharmaceutical Industries is the larger company by market cap ($45.42 billion vs $32.06 billion), about 1.4 times the size, while Royalty Pharma is growing revenue faster (+5.1% vs +4.3%).
On valuation, Royalty Pharma trades at a lower forward P/E (9.7x vs 12.6x for Teva Pharmaceutical Industries). Royalty Pharma pays a dividend yielding 1.64%, while Teva Pharmaceutical Industries does not currently pay one. Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus 8.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RPRX | TEVA |
|---|---|---|
| Share price | $55.49 | $38.94 |
| Market cap | $32.06B | $45.42B |
| 1-day change | -2.24% | -0.61% |
| YTD return | +46.89% | +25.54% |
| 1-year return | +57.23% | +95.22% |
| 5-year return | +47.85% | +304.75% |
| P/E ratio (TTM) | 29.52 | 64.90 |
| Forward P/E | 9.68 | 12.60 |
| EPS (TTM) | $1.88 | $0.60 |
| Dividend yield | 1.64% | 0.00% |
| Annual dividend | $0.91 | $0.00 |
| Revenue (latest FY) | $2.38B | $17.26B |
| Revenue growth (YoY) | +5.06% | +4.32% |
| Net income (latest FY) | $770.95M | $1.41B |
| Gross margin | — | 51.79% |
| Operating margin | 65.58% | 12.50% |
| Net margin | 32.42% | 8.17% |
| 52-week high | $64.38 | $40.79 |
| 52-week low | $35.23 | $18.83 |
| Distance from 52-week high | -13.81% | -4.54% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +17.82% | +16.33% |
| Average volume | 2.93M | 5.29M |
| Shares outstanding | 445.28M | 1.17B |
| Employees | 100 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TEVA has outperformed RPRX by 38.0 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (64.9x vs 29.5x trailing P/E).
- Royalty Pharma offers a meaningfully higher dividend yield (1.64% vs 0.00%).
- Royalty Pharma is more profitable, keeping 32.4 cents of every revenue dollar as net income versus 8.2 cents for Teva Pharmaceutical Industries.
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
RPRX vs TEVA FAQ
Which is bigger, Royalty Pharma or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.42B compared with $32.06B for Royalty Pharma (RPRX).
Which stock has performed better over the past year, RPRX or TEVA?
TEVA returned +95.22% over the past 12 months, compared with +57.23% for RPRX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, RPRX or TEVA?
RPRX has the lower trailing P/E at 29.5, versus 64.9 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Royalty Pharma or Teva Pharmaceutical Industries?
Royalty Pharma pays a dividend yielding 1.64%, while Teva Pharmaceutical Industries does not currently pay a regular dividend.
Are Royalty Pharma and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.